Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01669720 · ClinicalTrials.gov registry record · Phase 2
Adjuvant Aflibercept for Metastatic Colorectal Cancer
A Phase 2 study, sponsored by Brown University.
- Terminated
- Registry status
- Phase 2
- Development phase
- 10
- Enrollment target
NCT01669720 is a Phase 2 study that was terminated before completion, run by Brown University. The registered enrollment target is 10 participants.
The verdict
NCT01669720, a Phase 2 study, was terminated before completion, sponsored by Brown University.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 10 participants
- Enrollment target
Study Summary
The main purpose of this study is to evaluate if aflibercept can reduce the chance that metastatic (spread of) colorectal cancer can grow back after finishing standard treatment. The study will also look at the side effects of aflibercept and the effect on quality of life.
Interventions
- DRUG Aflibercept
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2012-12 |
| Est. Completion | 2016-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01669720
The ClinicalTrials.gov registry entry for NCT01669720 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Brown University, which has 231 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Aflibercept is the first listed.
NCT01669720 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01669720 about?
NCT01669720 is a clinical study titled "Adjuvant Aflibercept for Metastatic Colorectal Cancer". The main purpose of this study is to evaluate if aflibercept can reduce the chance that metastatic (spread of) colorectal cancer can grow back after finishing standard treatment. The study will also look at the side effects of aflibercept and the effect on quality of life.
What is the current status of trial NCT01669720?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 10 participants. The study started on 2012-12. Estimated completion is 2016-01.
What interventions are being tested in trial NCT01669720?
The interventions under investigation include: Aflibercept (DRUG).
Who is sponsoring clinical trial NCT01669720?
This trial is sponsored by Brown University, which has 231 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.